ICDDR-B is connected with global vaccine evaluation coalition
International Center for Diarrheal Disease Research, Bangladesh (ICDDR-B) has been connected with Coalition for Epidemic Preparedness Innovation (CEPI).
ICDDR-B is one of the five organizations selected by the global network ‘Coalition for Epidemic Preparedness Innovations’ (CEPI) to evaluate and compare the immunosuppressant potential of the corona vaccine.
This information was given in a press release sent from ICDDR-B on Friday (October 2).
The research centers initially selected on the global network are Nexelis (Canada), Public Health England (UK), Vismederisrol (Italy), Viroclinics-DDL (Netherlands), ICDDR- B (Bangladesh) and The Transliteration Health Sciences and Technological Institute of (India).
ICDDR-B has been added to the laboratory network that has been set up centrally to verify the reliability of potential corona vaccines discovered and comparative analysis of immunity, the release said. ICDDR-B is one of the five laboratories in this network.
John D. Clements, Executive Director of ICDDR-B said, without this it is not possible to make meaningful and logical comparisons between multiple vaccines. At the same time, it is not possible to verify which vaccine is most important for public health, he said. We welcome CEPI's initiative to build a global central network to do this. We also thank ICDDR-B for selecting an organization with decades of experience in vaccine evaluation. We will play a role in this network with utmost sincerity.
Note that CEPI is a Norwegian-based charity. It was established in August 2016 in Davos, Switzerland. They assist in the development of vaccines for serious infectious diseases. The founders of this organization are India, Norway and the Bill & Melinda Gates Foundation.